Alto Neuroscience (ANRO) Competitors

Alto Neuroscience (NYSE:ANRO) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.

Which has higher valuation & earnings, ANRO or TERN?

Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$36.31M	-$2.54	-0.97
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.13	-2.92

Does the MarketBeat Community believe in ANRO or TERN?

Terns Pharmaceuticals received 27 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 84.21% of users gave Alto Neuroscience an outperform vote while only 59.72% of users gave Terns Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Alto Neuroscience	Outperform Votes 16 84.21%	Underperform Votes 3 15.79%
Terns Pharmaceuticals	Outperform Votes 43 59.72%	Underperform Votes 29 40.28%

Is ANRO or TERN more profitable?

Terns Pharmaceuticals' return on equity of -32.76% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-49.28%	-33.52%
Terns Pharmaceuticals	N/A	-32.76%	-31.33%

Do analysts rate ANRO or TERN?

Alto Neuroscience currently has a consensus price target of $15.40, indicating a potential upside of 523.48%. Terns Pharmaceuticals has a consensus price target of $18.38, indicating a potential upside of 456.82%. Given Alto Neuroscience's higher probable upside, equities research analysts clearly believe Alto Neuroscience is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Which has more volatility & risk, ANRO or TERN?

Alto Neuroscience has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500.

Does the media prefer ANRO or TERN?

In the previous week, Terns Pharmaceuticals had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 6 mentions for Terns Pharmaceuticals and 2 mentions for Alto Neuroscience. Terns Pharmaceuticals' average media sentiment score of 1.48 beat Alto Neuroscience's score of 0.81 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Terns Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in ANRO or TERN?

98.3% of Terns Pharmaceuticals shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Terns Pharmaceuticals beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.